BRAND NAME DISCOUNTS TO PBMs MAY NOT BE LONG-TERM

BRAND NAME DISCOUNTS TO PBMs MAY NOT BE LONG-TERM cost control mechanism and are "not likely to continue" if pharmaceutical benefit management companies "become the dominant payer in the prescription market," according to a report by PRIME Institute Director Stephen Schondelmeyer, PhD. The report, entitled "Competition and Pricing Issues in the Pharmaceutical Market," was released at an Aug, 4 press conference sponsored by NARD and the National Association of Chain Drug Stores.